Active stocks on the 8th (morning session) - JINS HOLDINGS, NAKAMURA CHOUKOU, GNI Group

JINS HOLDINGS Inc. <3046> shares accelerated their gains on Monday. The stock rose over 10% at one point, renewing its year-to-date high and coming within reach of the key 9,000 yen level. Following Friday's close, the company disclosed that same-store sales in May increased 17.2% year-on-year, marking significant growth. On an all-store basis, sales surged 26.4% year-on-year. While JINS HOLDINGS' monthly sales have remained strong since the start of the current fiscal year in September 2025, May's growth rate was particularly remarkable following the substantial gains in April, drawing market attention. May had two more holidays than the prior year, and various promotional measures successfully captured robust inbound and seasonal demand, driving sales higher. The strong performance fueled buying interest, while on the supply-demand front, upside resistance eased as margin buying has been steadily unwound.

NAKAMURA CHOUKOU CO., LTD. <6166> shares locked at their daily limit-up ceiling for consecutive sessions. The company's consolidated financial results for the fiscal year ended March 2026, announced on May 14, showed an operating loss of 163.00 million yen, and the firm forecasts an operating loss of 160.00 million yen for the current fiscal year. The ordinary profit outlook marks a fourth consecutive year of losses, which sent the stock plunging following the earnings release before it hit a low of 435 yen on June 3. While NAKAMURA CHOUKOU plans to expand mass production of nozzles for new material mounting machines and promote sales of suction collets in the semiconductor sector this fiscal year, market participants have recently focused on its nano-sized zeolite, which is projected to see growth in applications such as rare earth recovery. A "Coming Soon" notice on the homepage of subsidiary Zeo Next's website has fueled speculation among retail investors that a new disclosure is imminent, attracting short-term speculative inflows seeking price volatility as buying momentum continued on Monday.

GNI Group Ltd. <2160> shares extended their gains for a sixth consecutive session on Monday. Following Friday's close, GNI Group announced it will acquire all shares of Tokyo-based Ayumi Pharmaceutical Holdings, a specialist in anti-rheumatic drugs and antipyretic analgesics, by September 30 to turn it into a subsidiary. Ayumi Pharmaceutical's antipyretic analgesic Calonal holds a market share of over 80.00% in the domestic acetaminophen sector. GNI Group expects the integration of Ayumi Pharmaceutical's domestic business operations to strengthen its domestic management base. The transaction is also anticipated to accelerate the introduction and deployment of the group's pipeline products, overseas pharmaceuticals, and biosimilars into the Japanese market. The acquisition price is 46.78 billion yen. Concurrently, the company announced the issuance of 9.97 million new shares through a third-party allotment to Ayumi Pharmaceutical's shareholders: BCP Asia AYM Holding, TOHO HOLDINGS CO.,LTD. <8129>, and Hisamitsu Pharmaceutical. The proceeds will fund the share acquisition, with the dilution rate from the allotment expected to be 17.89%.

*This may contain unconfirmed information. Please make stock trading decisions at your own risk and judgment.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.